{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T13:30:19Z","timestamp":1795095019608,"version":"4.10.2"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>Describe a case of post-pneumonectomy vasoplegia managed with angiotensin II. Plasma renin activity was measured at specific time intervals to describe the relationship between endogenous renin activity and exogenous angiotensin II supplementation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Design:<\/jats:title>\n            <jats:p>Case report.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Setting:<\/jats:title>\n            <jats:p>Spectrum Health Cardiothoracic Critical Care Unit.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients:<\/jats:title>\n            <jats:p>Fifty-seven-year-old male.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>None.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Measurements and Main Results:<\/jats:title>\n            <jats:p>Plasma renin activity at five pre-determined time points. Angiotensin II caused a significant increase in mean arterial pressure and a rapid reduction in catecholamine vasopressor doses from 0.75 to 0.31 mcg\/kg\/min norepinephrine equivalents. Plasma renin activity drawn immediately before angiotensin II initiation was 40 ng\/mL\/hr (normal, 0.6\u20133.0 ng\/mL\/hr) with resultant drop to 22 and 12 ng\/mL\/hr at 2 and 6 hours after angiotensin II initiation, respectively. The patient suffered no end-organ damage and achieved a positive outcome, discharging home on postoperative day 11.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Exogenous angiotensin II reduced catecholamine vasopressor doses and had an apparent effect in reducing endogenous renin production in this case. Prospective research is warranted to determine the utility of angiotensin II and to better understand it effects on the dysfunctional renin-angiotensin-aldosterone system during vasoplegic shock.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ccm.0000000000004502","type":"journal-article","created":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T23:01:43Z","timestamp":1596582103000},"page":"e912-e915","source":"Crossref","is-referenced-by-count":13,"title":["Use of Angiotensin II in Severe Vasoplegia After Left Pneumonectomy Requiring Cardiopulmonary Bypass: A Renin Response Analysis"],"prefix":"10.1097","volume":"48","author":[{"given":"Brian","family":"Trethowan","sequence":"first","affiliation":[{"name":"Department of Cardiac Anesthesia, Grand Rapids, MI."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Michaud","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Spectrum Health, Grand Rapids, MI."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Fifer","sequence":"additional","affiliation":[{"name":"Spectrum Health Medical Group, Grand Rapids, MI."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,7,8]]},"reference":[{"key":"R1-20230728","first-page":"52","article-title":"Vasoplegia treatments: The past, the present and the future.","volume":"22","author":"Levy","year":"2018","journal-title":"CCM Rev"},{"key":"R2-20230728","doi-asserted-by":"crossref","first-page":"e013108","DOI":"10.1161\/JAHA.119.013108","article-title":"Predictors and clinical outcomes of vasoplegia in patients bridged to heart transplantation with continuous-flow left ventricular assist devices.","volume":"8","author":"Asleh","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"R3-20230728","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1056\/NEJMoa1704154","article-title":"Angiotensin II for the treatment of vasodilatory shock.","volume":"377","author":"Khanna","year":"2017","journal-title":"N Engl J Med"},{"key":"R5-20230728","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s13054-018-2225-4","article-title":"Angiotensin in ECMO patients with refractory shock.","volume":"22","author":"Ostermann","year":"2018","journal-title":"Crit Care"},{"key":"R6-20230728","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.athoracsur.2018.11.047","article-title":"Use of angiotensin II for post cardiopulmonary bypass vasoplegic syndrome.","volume":"108","author":"Evans","year":"2019","journal-title":"Ann Thorac Surg"},{"key":"R7-20230728","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1053\/j.jvca.2019.03.004","article-title":"Synthetic human angiotensin II for postcardiopulmonary bypass vasoplegic shock.","volume":"33","author":"Wieruszewski","year":"2019","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"R8-20230728","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1053\/j.jvca.2019.03.054","article-title":"Use of angiotensin II for vasoplegic shock in a combined heart and liver transplant recipient with systolic anterior motion physiology.","volume":"33","author":"Wieruszewski","year":"2019","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"R9-20230728","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1186\/s13054-018-2202-y","article-title":"Angiotensin converting enzyme defects in shock: Implications for future therapy.","volume":"22","author":"Chawla","year":"2018","journal-title":"Crit Care"},{"key":"R10-20230728","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13054-020-2733-x","article-title":"Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock.","volume":"24","author":"Bellomo","year":"2020","journal-title":"Crit Care"},{"key":"R11-20230728","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.2147\/TCRM.S150434","article-title":"Angiotensin II: A new therapeutic option for vasodilatory shock.","volume":"14","author":"Bussard","year":"2018","journal-title":"Ther Clin Risk Manag"},{"key":"R12-20230728","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1161\/CIRCRESAHA.113.300308","article-title":"Adrenergic nervous system in heart failure: Pathophysiology and therapy.","volume":"113","author":"Lymperopoulos","year":"2013","journal-title":"Circ Res"},{"key":"R13-20230728","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/CCM.0000000000003544","article-title":"Renin as a marker of tissue-perfusion and prognosis in critically ill patients.","volume":"47","author":"Gleeson","year":"2019","journal-title":"Crit Care Med"},{"key":"R14-20230728","first-page":"1248","article-title":"Plasma renin concentration as a predictor of outcome in a medical intensive care setting: A retrospective pilot study.","volume":"78","author":"Barbieri","year":"2012","journal-title":"Minerva Anestesiol"},{"key":"R15-20230728","doi-asserted-by":"crossref","first-page":"142","DOI":"10.4266\/kjccm.2017.00094","article-title":"Implications of plasma renin activity and plasma aldosterone concentration in critically ill patients with septic shock.","volume":"32","author":"Chung","year":"2017","journal-title":"Korean J Crit Care Med"},{"key":"R16-20230728","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s00134-003-1986-6","article-title":"Hyperreninemic hypoaldosteronism: A possible etiological factor of septic shock-induced acute renal failure.","volume":"29","author":"du Cheyron","year":"2003","journal-title":"Intensive Care Med"},{"key":"R17-20230728","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s00134-007-0864-z","article-title":"Hyperreninemic hypoaldosteronism syndrome, plasma concentrations of interleukin-6 and outcome in critically ill patients with liver cirrhosis.","volume":"34","author":"du Cheyron","year":"2008","journal-title":"Intensive Care Med"}],"container-title":["Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCM.0000000000004502","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T11:53:40Z","timestamp":1690545220000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCM.0000000000004502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,8]]},"references-count":16,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/ccm.0000000000004502","relation":{},"ISSN":["0090-3493"],"issn-type":[{"value":"0090-3493","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,8]]}}}